natgillin/translations-raw huggingface dataset:
In clinical studies, the dulaglutide safety profile in patients with moderate renal impairment was similar to the overall type 2 diabetes population.
U kliničkim je ispitivanjima profil sigurnosti dulaglutida u bolesnika s umjerenim oštećenjem bubrežne funkcije bio sličan onome u cjelokupnoj populaciji sa šećernom bolešću tipa 2.
In clinical studies, the following undesirable effects have been reported: Common reported side effects included:
U kliničkim ispitivanjima prijavljene su sljedeće nuspojave: Često prijavljene nuspojave uključuju:
In clinical studies, the incidence of important elevations in creatine phosphokinase (CK ≥ 3 times the ULN, < 5 times the ULN) was 1.92% for patients treated with Pravafenix.
U kliničkim ispitivanjima incidencija značajnih povišenja kreatin fosfokinaze (KF ≥ 3puta GGN, < 5 puta GGN) bila je kod 1,92% bolesnika liječenih Pravafenixom.
In clinical studies, the occurrence of ejaculation with reduced or no semen has been observed during treatment with silodosin (see section 4.8), due to the pharmacodynamic properties of silodosin.
U kliničkim je ispitivanjima za vrijeme liječenja silodozinom primijećena pojava ejakulacije sa smanjenom količinom sjemena ili bez sjemena (vidjeti dio 4.8), zbog farmakodinamičkih svojstava silodozina.
In clinical studies, the safety profile of Pandemic influenza vaccine H5N1 MedImmune was comparable to the safety profile of the seasonal vaccines T/LAIV and Fluenz Tetra (see section 5.1 for more information).
U kliničkim ispitivanjima, sigurnosni profil Pandemijskog cjepiva protiv influence H5N1 MedImmune bio je usporediv sa sigurnosnim profilom sezonskih cjepiva T/LAIV i Fluenz Tetra (za više informacija vidjeti dio 5.1).
In clinical studies, there was limited representation of patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) (see section 5.2).
U klinička je ispitivanja bio uključen ograničen broj bolesnika s teškim oštećenjem bubrežne funkcije (koje se definiralo kao eGFR <30 ml/min/1,73 m2) (vidjeti dio 5.2).
In clinical studies, there were no reports of anaphylaxis.
U kliničkim ispitivanjima nije bilo zabilježenih slučajeva anafilaksije.
In clinical studies, transaminase elevations occurred at any time during treatment although the majority occurred within the first 12 months.
U kliničkim ispitivanjima povišenja transaminaza javljalo se u bilo kojem trenutku za vrijeme liječenja, iako ih se većina javila tijekom prvih 12 mjeseci.
In clinical studies, treatment with SPRYCEL was continued until disease progression or until no longer tolerated by the patient.
U kliničkim je ispitivanjima liječenje lijekom SPRYCEL trajalo do napredovanja bolesti ili do razvoja nepodnošljivosti lijeka kod bolesnika.
In clinical studies, undesirable dopaminergic adverse reactions, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination.
U kliničkim su studijama neželjeni dopaminergički učinci, npr. diskinezija, bili češći u bolesnika koji su primali entakapon i agoniste dopamina (kao što je bromokriptin), selegilin ili amantadin, u usporedbi s onima koji su primali placebo s tom kombinacijom.
In clinical studies, urticaria and rare cases of anaphylactic reaction to Cosentyx were observed (see also section 4.4).
U kliničkim ispitivanjima uočena je urtikarija i rijetki slučajevi anafilaktičke reakcije na Cosentyx (vidjeti također dio 4.4).
In clinical studies, zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring.
U kliničkim ispitivanjima zoledronatna kiselina primjenjivala se istodobno s uobičajeno primjenjenim antitumorskim lijekovima, diureticima, antibioticima i analgeticima bez klinički vidljivih interakcija.
In clinical studies, zoledronic acid, used as indicated in sections 4.1 and 4.2, has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring.
U kliničkim se ispitivanjima zoledronatna kiselina, korištena sukladno navedenom u dijelovima 4.1 i 4.2, primjenjivala istodobno s često davanim antitumorskim lijekovima, diureticima, antibioticima i analgeticima bez klinički vidljivih interakcija.
In clinical study CIR 217 the safety, infectivity, and immunogenicity of a live attenuated, vaccine derived from A/Vietnam/1203/2004 (H5N1) influenza isolate were evaluated in 21 subjects who received one 106.7 median tissue culture infectious dose (TCID50) , with 18 of those subjects receiving a second dose 4-8 weeks later.
U kliničkom ispitivanju CIR 217 procijenjeni su sigurnost, infektivnost i imunogenost živog atenuiranog cjepiva proizvedenog iz izolata virusa influence A/Vietnam/1203/2004 (H5N1) na 21 ispitaniku koji su primili jednu dozu virusnog cjepiva od 106,7 TCID50 (infektivna doza tkivne kulture), gdje je 18 od tih ispitanika primilo drugu dozu nakon 4 do 8 tjedana.
In clinical study CIR 239 the safety, infectivity, and immunogenicity of a live attenuated vaccine derived from A/Hong Kong/213/2003 (H5N1) influenza isolate were evaluated in 17 subjects who received one dose of 107.5 TCID50 of the vaccine intranasally in isolation, with 16 of those subjects receiving a second dose 4-8 weeks later.
U kliničkom ispitivanju CIR 239 procijenjeni su sigurnost, infektivnost i imunogenost živog atenuiranog cjepiva proizvedenog iz izolata virusa influence A/Hong Kong/213/2003 (H5N1) na 17 ispitanika koji su u uvjetima izolacije primili intranazalno jednu dozu virusnog cjepiva od 107,5 TCID50, od kojih je 16 ispitanika primilo drugu dozu nakon 4 do 8 tjedana.
In clinical study D9902B (IMPACT), 237 out of the 512 patients randomized were evaluated for the development of humoral or cellular immune responses (T cell proliferation and gamma-interferon (γIFN) ELISPOT) to the target antigens at baseline, and at Weeks 6, 14, and 26.
U kliničkom ispitivanju D9902B (IMPACT), 237 od ukupno 512 randomiziranih bolesnika evaluirano je u odnosu na razvoj humoralnog ili staničnog imunološkog odgovora (proliferacija T stanica i mjerenje interferona gama (γIFN) ELISPOT testom) na ciljne antigene na početku liječenja te u 6., 14. i 26. tjednu liječenja.
In clinical study MI-CP217 the safety and descriptive immunogenicity of a live attenuated monovalent influenza virus vaccine (derived from A/California/7/2009) developed for the 2009 H1N1 pandemic were evaluated in a total of 326 randomised subjects (259 subjects monovalent vaccine; 65 subjects placebo) and 324 subjects received one dose of investigational product.
U kliničkom ispitivanju MI-CP217, sigurnost i deskriptivna imunogenost živog atenuiranog monovalentnog cjepiva protiv influence (proizvedenog iz A/California/7/2009) razvijenog za pandemiju H1N1 2009. procijenjeno je na ukupno 326 randomiziranih ispitanika (259 ispitanika primilo je monovalentno cjepivo; 65 ispitanika primilo je placebo), te su 324 ispitanika primila jednu dozu ispitivanog lijeka.
In clinical trial 131 adults and 123 elderly were exposed to two doses of the 7.5 µg Focetria.
U kliničkom su ispitivanju 131 odrasla i 123 starije osobe bile izložene s dvije doze Focetrie od 7,5 µg.
In clinical trials 69 patients who relapsed or were refractory to initial treatment (zoledronic acid 4 mg, 8 mg or pamidronate 90 mg) were retreated with zoledronic acid 8 mg.
U kliničkim je ispitivanjima 69 bolesnika s relapsom ili bolešću otpornom na početno liječenje (zoledronatna kiselina u dozi od 4 mg, 8 mg ili pamidronat u dozi od 90 mg) bilo liječeno zoledronatnom kiselinom u dozi od 8 mg.
In clinical trials a similar safety profile has been observed in subjects with prior or current HPV infection as compared to subjects negative for oncogenic HPV DNA or seronegative for HPV-16 and HPV-18 antibodies.
U kliničkim je ispitivanjima u osoba s prijašnjom ili postojećom HPV infekcijom zabilježen sličan profil nuspojava kao u osoba negativnih na DNA onkogenih HPV tipova ili seronegativnih na protutijela protiv HPV-16 i HPV-18.
In clinical trials a thin layer of Raplixa produced doses that typically ranged from 0.3 to 2 g.
U kliničkim ispitivanjima, tanki sloj lijeka Raplixa primjenjivan je u dozama koje su se obično kretale u rasponu od 0,3 g do 2 g.
In clinical trials adverse events seen on abrupt treatment discontinuation occurred in approximately 45% of patients treated with Duloxetine Lilly and 23% of patients taking placebo.
U kliničkim su se ispitivanjima nuspojave nakon naglog prekida liječenja pojavile u približno 45% bolesnika liječenih lijekom Duloksetin Lilly i u 23% bolesnika koji su uzimali placebo.
In clinical trials adverse events seen on abrupt treatment discontinuation occurred in approximately 45% of patients treated with Xeristar and 23% of patients taking placebo.
U kliničkim su se ispitivanjima nuspojave nakon naglog prekida liječenja pojavile u približno 45% bolesnika liječenih lijekom Xeristar i u 23% bolesnika koji su uzimali placebo.
In clinical trials and post-marketing experience there have been reports of seizures in patients with or without a history of seizures, treated with CHAMPIX.
U kliničkim ispitivanjima i iskustvima nakon što je lijek stavljen na tržište, prijavljeni su napadaji u bolesnika s ili bez napadaja u anamnezi, a koji su liječeni CHAMPIX-om,.
In clinical trials and post-marketing experience there have been reports of seizures in patients with or without a history of seizures, treated with CHAMPIX.
U kliničkim ispitivanjima i iskustvima nakon što je lijek stavljen na tržište, prijavljeni su napadaji u bolesnika s ili bez napadaja u anamnezi, a koji su liječeni CHAMPIX-om.
In clinical trials approximately 5% of patients were treated at doses below 1.1 mg (1.5 mg of salt).
U kliničkim ispitivanjima je oko 5% bolesnika liječeno dozama nižim od 1,1 mg baze (1,5 mg soli).
In clinical trials at the recommended dose (2 mg/kg), robenacoxib reduced pain and inflammation in dogs undergoing orthopaedic or soft tissue surgery.
U kliničkim ispitivanjima preporučene doze (2 mg/kg), robenakoksib je smanjio bol i upalu u pasa koji su bili podvrgnuti ortopedskim kirurškim zahvatima ili onima na mekom tkivu.
In clinical trials C95-132 and I95-143, Ribavirin + interferon alfa-2b combination therapy proved to be significantly more effective than interferon alfa-2b monotherapy (a doubling in sustained response).
U kliničkim ispitivanjima C95-132 i I95-143 se ribavirin u kombinaciji s interferonom alfa-2b pokazao značajno djelotvornijim od monoterapije interferonom alfa-2b (udvostručen trajan odgovor na liječenje).
In clinical trials Cervarix has been shown to prevent HPV related diseases in women aged 15 years and older.
U kliničkim ispitivanjima dokazano je da Cervarix sprječava bolesti uzrokovane HPV-om u žena u dobi od 15 i starijih.
In clinical trials Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.
U kliničkim se istraživanjima Cetrotide koristio s humanim menopauzalnim gonadotropinom (HMG), no ograničeno iskustvo s rekombinantnim folikulostimulirajućim hormonom (FSH) upućivalo je na sličnu djelotvornost.
In clinical trials conducted in a broad range of indications and at a wide range of doses (from
U kliničkim ispitivanjima provedenima u velikom broju indikacija i u širokom rasponu doza (od
In clinical trials doses of up to 4 mg in monthly intervals have been used and isolated cases of overdoses with 8 mg occurred.
U kliničkim ispitivanjima primjenjivane su doze do 4 mg u mjesečnim intervalima i u izoliranim slučajevima došlo je do predoziranja s dozom od 8 mg.
In clinical trials fewer than 1% (17/3189) of patients experienced a serious IRR.
Manje od 1% (17/3189) bolesnika u kliničkim ispitivanjima imalo je ozbiljnu reakciju povezanu s infuzijom.
In clinical trials first degree AV block (PR prolongation > 220 msec) developed in 3% of patients within 2 hours of Rapiscan administration; transient second degree AV block with one dropped beat was observed in one patient receiving Rapiscan.
U kliničkim ispitivanjima AV blok prvog stupnja (produženi PR interval > 220 msek) razvio se u 3% bolesnika unutar 2 sata od primjene Rapiscana; prolazni AV blok drugog stupnja s neprovedenim jednim QRS-om primijećen je kod jednog bolesnika koji je primio Rapiscan.
In clinical trials for proliferating infantile haemangioma, the most frequently reported adverse reactions in infant treated with HEMANGIOL were sleep disorders, aggravated respiratory tract infections such as bronchitis and bronchiolitis associated with cough and fever, diarrhoea, and vomiting.
U kliničkim ispitivanjima za proliferirajući infantilni hemangiom, najčešće zabilježene nuspojave kod dojenčadi liječene HEMANGIOL-om bili su poremećaji spavanja, teške infekcije dišnih puteva, kao što su bronhitis i bronhiolitis povezan s kašljem i povišenom tjelesnom temperaturom, proljev i povraćanje.
In clinical trials for the approved indications and post-marketing, both increase and decrease in serum prolactin as compared to baseline was observed with aripiprazole (section 5.1).
U kliničkim ispitivanjima u odobrenim indikacijama i nakon stavljanja lijeka u promet, opaženo je i povećanje i smanjenje prolaktina u serumu uz aripiprazol u usporedbi s početnim vrijednostima (dio 5.1).
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Aerius tablets were reported in 3 % of patients in excess of those treated with placebo.
U kliničkim ispitivanjima kod različitih indikacija, uključujući alergijski rinitis i kroničnu idiopatsku urtikariju, pri preporučenoj dozi od 5 mg na dan, kod primjene lijeka Aerius prijavljene su nuspojave u 3% više bolesnika nego u onih koji su primali placebo.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Azomyr tablets were reported in 3 % of patients in excess of those treated with placebo.
U kliničkim ispitivanjima kod različitih indikacija, uključujući alergijski rinitis i kroničnu idiopatsku urtikariju, pri preporučenoj dozi od 5 mg na dan, kod primjene Azomyr tableta prijavljene su nuspojave u 3% više bolesnika nego u onih koji su primali placebo.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Azomyr were reported in 3 % of patients in excess of those treated with placebo.
U kliničkim ispitivanjima kod različitih indikacija, uključujući alergijski rinitis i kroničnu idiopatsku urtikariju, pri preporučenoj dozi od 5 mg na dan, kod primjene lijeka Azomyr prijavljene su nuspojave u 3% više bolesnika nego u onih koji su primali placebo.
In clinical trials in cancer patients the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10%, and severe in 3% of patients.
Tijekom kliničkih ispitivanja bolesnika s rakom, najčešći neželjeni učinak bila je mišićno-koštana bol koja je bila blaga ili umjerena u 10% bolesnika i teška koja se javila u 3% bolesnika.
In clinical trials in cancer patients the most frequent undesirable effect was musculoskeletal pain which was mild or moderate in 10%, and severe in 3% of patients.
U kliničkim ispitivanjima bolesnika s malignom bolešću najčešća nuspojava bila je mišićno-koštana bol koja je bila blaga ili umjerena u 10 % bolesnika i teška u 3 % bolesnika.
In clinical trials in cats this product reduced pain and inflammation associated with musculoskeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids.
U kliničkim ispitivanjima na mačkama, tablete robenakoksiba smanjile su bol i upalu koje su bile povezane s mišićno-koštanim poremećajima te su smanjile potrebu za terapijom spašavanja kad su se davale kao premedikacija u slučaju ortopedskih kirurških zahvata, a u kombinaciji s opioidima.
In clinical trials in cats, robenacoxib tablets reduced pain and inflammation associated with musculoskeletal disorders and reduced the need for rescue treatment when given as premedication in case of orthopaedic surgery, in combination with opioids.
U kliničkim ispitivanjima na mačkama, tablete robenakoksiba smanjile su bol i upalu koje su bile povezane s mišićno-koštanim poremećajima te su smanjile potrebu za terapijom spašavanja kad su se davale kao premedikacija u slučaju ortopedskih kirurških zahvata, a u kombinaciji s opioidima.
In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0
U kliničkim ispitivanjima s cIAI-ovima (engl. complicated intra-abdominal infections), najčešći oblik infekcije u bolesnika koji su liječeni tigeciklinom bio je komplicirani apendicitis (50,3%), a potom slijede ostale rjeđe prijavljene dijagnoze poput kompliciranog kolecistitisa (9,6%), perforacija crijeva (9,6%), intraabdominalnog apscesa (8,7%), perforacije želučanog ili duodenalnog ulkusa (8,3%), peritonitis (6,2%) i komplicirani divertikulitis (6,0%).
In clinical trials in CML, drug discontinuation for drug-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy.
U kliničkim ispitivanjima KML-a je ukidanje lijeka zbog nuspojava povezanih s njegovom primjenom zapaženo u2,4% novodijagnosticiranih bolesnika, 4% bolesnika u kasnoj kroničnoj fazi nakon neuspjeha terapije interferonom, 4% bolesnika u ubrzanoj fazi nakon neuspjeha terapije interferonom i 5% bolesnika u blastičnoj krizi nakon neuspjeha terapije interferonom.
In clinical trials in CML, medicinal product discontinuation for medicinal product-related adverse reactions was observed in 2.4% of newly diagnosed patients, 4% of patients in late chronic phase after failure of interferon therapy, 4% of patients in accelerated phase after failure of interferon therapy and 5% of blast crisis patients after failure of interferon therapy.
U kliničkim ispitivanjima KML-a je ukidanje lijeka zbog nuspojava povezanih s njegovom primjenom zapaženo u 2,4% novodijagnosticiranih bolesnika, 4% bolesnika u kasnoj kroničnoj fazi nakon neuspjeha terapije interferonom, 4% bolesnika u ubrzanoj fazi nakon neuspjeha terapije interferonom i 5% bolesnika u blastičnoj krizi nakon neuspjeha terapije interferonom.
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
Primjena olanzapina u liječenju psihoza povezanih s dopaminskim agonistima u bolesnika s Parkinsonovom bolešću se ne preporučuje.
In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see also section 4.4).
U kliničkim ispitivanjima u starijih bolesnika s demencijom, liječenje olanzapinom bilo je povezano s povišenom incidencijom smrti i cerebrovaskularnih nuspojava u odnosu na placebo (vidjeti dio 4.4).
In clinical trials in epilepsy patients the incidence rate of reported first degree AV Block is uncommon, 0.7%, 0%, 0.5% and 0% for lacosamide 200 mg, 400 mg, 600 mg or placebo, respectively.
U kliničkim istraživanjima u bolesnika s epilepsijom stopa incidencije prijavljenih AV-blokova prvog stupnja manje je česta te iznosi 0,7%, 0%, 0,5% koji su uzimali lakozamid u dozi od 200 mg, 400 mg, 600 mg odnosno 0% za placebo.
In clinical trials in Friedreich’s Ataxia, 32 patients between the ages of 8 and 11 years and 91 patients between the ages of 12 and 17 years received idebenone at ≥ 900 mg/day for up to 42 months.
U kliničkim ispitivanjima Friedreichove ataksije, 32 bolesnika u dobi između 8 i 11 godina te 91 bolesnik u dobi između 12 i 17 godina primili su idebenon u dozi od ≥ 900 mg/dan tijekom razdoblja od najviše 42 mjeseca.
In clinical trials in mild to severe dementia, involving 1,784 patients treated with memantine and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with memantine did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
U kliničkim ispitivanjima blage do teške demencije, u kojima je 1784 bolesnika liječeno memantinom, a 1595 ih je dobivalo placebo, sveukupna stopa incidencije nuspojava u skupini liječenoj memantinom nije se razlikovala od one v skupini koja je primala placebo; nuspojave su uglavnom bile blage do umjerene težine.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
Na početku ovih ispitivanja bolesnici su morali biti stabilni na najnižoj učinkovitoj dozi antiparkinsonika (agonisti dopamina) te su na istom antiparkinsoniku i pri istoj dozi morali ostati tijekom cijelog ispitivanja.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
U kliničkim ispitivanjima s bolesnicima s Parkinsonovom bolešću koji su razvili psihozu uslijed primjene lijekova (dopaminskih agonista), pogoršanje simptoma parkinsonizma i halucinacije prijavljene su vrlo često i učestalije nego kod ispitanika koji su dobivali placebo.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
U kliničkim ispitivanjima u bolesnika s psihozom uzrokovanom lijekom (agonisti dopamina) povezanom s Parkinsonovom bolesti, vrlo često je zabilježeno pogoršanje simptoma parkinsonizma i halucinacija i češće nego s placebom.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
U kliničkim ispitivanjima u bolesnika s psihozom uzrokovanom lijekom (agonisti dopamina) povezanom s Parkinsonovom bolešću vrlo često je zabilježeno pogoršanje simptoma parkinsonizma i halucinacija, češće nego s placebom.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
U kliničkim ispitivanjima u bolesnika s psihozom uzrokovanom lijekovima (agonisti dopamina) povezanom s Parkinsonovom bolešću vrlo često je zabilježeno pogoršanje simptoma parkinsonizma i halucinacija i češće nego s placebom.
In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson’s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.
U kliničkim ispitivanjima u bolesnika s psihozom uzrokovanom lijekovima (agonisti dopamina) povezanom s Parkinsonovom bolešću, vrlo često je zabilježeno pogoršanje simptoma parkinsonizma i halucinacija i češće nego s placebom.